Welcome back, traders! After a phenomenal run in 2025, we aren’t slowing down. Our goal is to bring that same winning energy and precise execution right here into 2026. To make sure you’re getting the most out of our research, we’ve launched additional platforms so you can get firsthand access to everything we’re doing. You can even head over to the iOS App Store and download ChartSwipe or subscribe to our Powerhouse newsletters—visit powerhouse.substack.com to get direct access to our email updates and community!
Now, let’s get down to business. We’ve been scanning the markets all weekend, looking for where the smart money is hiding. Right now, the name of the game is momentum. We want high-probability setups, massive volume confirmation, and rock-solid earnings to back up the technicals.
Here’s what is flashing bright green on our radar right now.
The Heavyweights: Large-Cap Momentum Leaders
Nvidia (NASDAQ: NVDA) – The Undisputed Champ
- The Vibe: AI isn’t going anywhere, and NVDA is still the absolute bellwether.
- The Setup: We are looking at a beautiful continuation breakout here. The stock is surfing right above its 50-day moving average. What we love seeing is the volume on the green days—that’s institutional money stepping in. If we get a clean push to new highs with volume pumping 30% above average, buckle up.
Eli Lilly and Company (NYSE: LLY) – Defensive Growth Done Right
- The Vibe: Tech is flashy, but healthcare is where the quiet, heavy capital goes to work.
- The Setup: LLY is boasting an incredibly strong, long-term uptrend and is consolidating right near its recent highs. With their earnings growth acting as an absolute fortress, this is the perfect rotation play. It’s an “old money” sleep-well-at-night stock that still gives us the breakout momentum we crave.
Spotlight Setup: Cardiol Therapeutics (NASDAQ: CRDL) 🚀
Alright, let’s talk biotech. While the large caps pay the bills, the biotech sector is where we find those potential incredible, asymmetric risk/reward setups—but only if the company has flawless clinical execution and a bulletproof balance sheet. Right now, Cardiol Therapeutics ($CRDL) is screaming potential high-conviction as they take aim at the massive $30 billion U.S. heart failure market.
$CRDL FEATURED IN THE WALLSTVAULT.COM
Here is why $CRDL is our top focus right now:
- Execution is Everything: $CRDL isn’t running on hype; they are running on late-stage, tangible data. They just crossed the 75% patient enrollment mark for their pivotal Phase III MAVERIC trial (targeting recurrent pericarditis). This puts them on an aggressive path toward top-line data and a potential NDA submission.
- Game-Changing Science: Their Phase II ARCHER trial data showed that CardiolRx™ actually significantly reduced left ventricular mass in patients with acute myocarditis. They aren’t just putting a band-aid on symptoms; they are actively modifying the disease.
- A “Sleep Well” Balance Sheet: The number one buzzkill in biotech momentum is surprise dilution. $CRDL completely took that off the table. After a series of heavily oversubscribed private placements and bought deals, their cash runway is fully locked and loaded deep into Q4 2027.
- Follow the Money: According to Whale Wisdom, a major fund has been accumulating a massive position. Anytime you see “Smart Money” loading up on a stock trading under $2, you have to pay attention.
The Gameplan Remember our golden rule: let the market prove it to you. Don’t front-run the breakouts. Wait for that close above resistance, make sure the RSI looks healthy, and demand to see that volume confirmation before you put your capital to work.
Let’s crush it this week!
Becoming a consistent trader is not easy.
Most fail.
At News On Wall Street we have a program.
Nothing is guaranteed but, we are opening the doors!
Text us at 844-722-9743.
LEGAL COMPLIANCE & DISCLOSURES
NOT FINANCIAL ADVICE – EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY All information provided by News On Wall Street (the “Publisher”) is strictly for educational and informational purposes only. Nothing contained herein constitutes, or is intended to constitute, investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. The Publisher is not a registered investment adviser, broker-dealer, or financial planner with any regulatory agency. We do not provide personalized investment recommendations and have no fiduciary duty to any reader or subscriber.
You should consult with a qualified, licensed financial professional (such as a registered investment adviser or broker-dealer) who can assess your individual financial situation, risk tolerance, investment objectives, and tax consequences before making any investment decision. Investing in micro-cap biotechnology stocks like Cardiol Therapeutics ($CRDL) carries extreme risk, including the potential for total loss of principal. Biotech companies frequently experience total failure of clinical programs, regulatory rejection, massive dilution, delisting, or bankruptcy. Volatility can be extreme, with shares sometimes moving 50% or more in a single day on news events.
HIGH-RISK WARNING SPECIFIC TO BIOTECHNOLOGY INVESTING Biotechnology investing is inherently binary and speculative. Most clinical-stage companies never generate profits, never receive regulatory approval, and ultimately result in significant or total investor losses. Factors that could cause actual results to differ materially from any expectations expressed here include (but are not limited to): failure of Phase II or Phase III clinical trials (such as the ARCHER or MAVERIC trials referenced), delays or denial of FDA or other regulatory approvals, manufacturing issues, competition from larger pharmaceutical companies, intellectual property challenges, dilution from future financings, changes in healthcare policy, clinical safety concerns, adverse events, inability to secure additional funding, loss of key personnel, and general market or economic conditions. Past clinical data is not a guarantee of future success in larger trials or commercialization.
FORWARD-LOOKING STATEMENTS SAFE HARBOR This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “project,” “may,” “will,” “could,” “should,” “potential,” “intend,” “forecast,” “target,” or similar expressions.
All forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve risks and uncertainties. These statements speak only as of the date they are made, and the Publisher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those expressed or implied due to the numerous risks outlined above and in Cardiol’s SEC filings (10-K, 10-Q, 8-K, etc.). Nothing in this report is a guarantee of future performance, clinical success, regulatory approval, commercialization, or stock price appreciation.
SEC RULE 17(b) DISCLOSURE (PAID PROMOTION / AWARENESS CAMPAIGN) News On Wall Street (the “Publisher”) has been compensated $100,000 in cash by Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) for the creation, distribution, and ongoing awareness efforts related to this report and associated content. This compensation covers the period from April 7, 2026, through May 27, 2026. The payment was made directly by the Company (or its agents) to the Publisher and constitutes a material conflict of interest.
This entire communication is a paid advertisement / sponsored awareness campaign. The Publisher was compensated specifically to publish, publicize, and circulate information regarding Cardiol’s securities. Under Section 17(b) of the Securities Act of 1933, this disclosure is required. Investors must assume that the Publisher’s objectivity is influenced by this relationship. THIS IS NOT INDEPENDENT RESEARCH. It is commissioned, paid-for promotional material. The Publisher is not acting as an independent analyst and does not claim to provide unbiased or impartial analysis.
CONFLICT OF INTEREST DISCLOSURE The Publisher and/or its principals, affiliates, officers, directors, employees, family members, or other associated parties may currently hold, or may in the future purchase or sell, positions in Cardiol Therapeutics ($CRDL) or any other securities mentioned without prior or subsequent notice to readers. The Publisher may buy or sell shares at any time, including before, during, or after the distribution of this report. This creates an inherent conflict of interest.
INFORMATION SOURCES, ACCURACY, AND LIABILITY Information in this report is derived from public sources believed to be reliable (Company press releases, SEC filings, etc.). However, the Publisher makes no representation or warranty as to the accuracy, completeness, or timeliness of any information provided. To the fullest extent permitted by law, News On Wall Street, its officers, directors, and affiliates shall not be liable for any direct, indirect, or consequential damages arising out of the use of this report, including trading losses or loss of profits.
PERFORM YOUR OWN DUE DILIGENCE (DYOR) Always conduct your own thorough independent research. Review Cardiol’s latest SEC filings at www.sec.gov, consult multiple independent sources, and speak with your own financial and legal advisors before investing. Do not rely solely on any paid promotional material.
By continuing to read or act upon any information provided by News On Wall Street, you acknowledge that you have read, understood, and agreed to this full Legal Compliance & Disclosures section in its entirety.
